Burning Rock Biotech (BNR)

• Market cap: $183M
• 1 day: 6.12%
• 5 days: -24.42%
• 1 month: -42.5%
• 3 months: -9.34%
• 6 months: 100.12%
• Year to date: -13.67%
• 1 year: 192.93%
• 5 years: -93.42%
• 10 years: -93.1%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Employees: 674